GlobeNewsWire

29 May 2026, 20:35 UTC · 2h ago

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Source · https://www.globenewswire.com/news-release/2026/05/29/3303823/0/en/Transactions-with-Shares-and-Linked-Securities-in-Genmab-A-S-Made-by-Managerial-Employees-and-Their-Closely-Associated-Persons.html

Read source

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Search tags

Story key points

2 claims · impact-rated

What matters in this story

1
Genmab A/S is increasing its share capital by 2,346 shares due to the exercise of employee warrants. — While the number of shares is negligible, any increase in share capital is technically dilutive to existing shareholders.
-0.10
2
Genmab A/S has disclosed transactions made in the company's shares by managerial employees and their closely associated persons. — The announcement is a regulatory compliance disclosure and does not specify the direction or volume of the trades.
+0.00

Ticker attribution

Model heads

Sentiment in this article

GMAB+0.00
The article consists of regulatory disclosures regarding insider transactions and share capital increases, which are neutral administrative events.

6 related stories

GlobeNewsWire
4h ago
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– HBSS
- biotechnology
- pharmaceuticals
Read

News Impact Screener — Catch market-moving news before the crowd

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

What matters in this story

Sentiment in this article

Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– HBSS

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

What matters in this story

Sentiment in this article

Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– HBSS

Relationships in this article

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

GOSSAMER BIO DEADLINE MONDAY JUNE 1st: Bragar Eagel & Squire, P.C. Urges Gossamer Bio, Inc. (NASDAQ:GOSS) Investors with Large Losses to Contact the Firm Before Monday June 1st

ALDEYRA DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 29 Deadline in Securities Class Action First Filed by the Firm - ALDX

AISIX Solutions Inc. Provides Status Report of Annual Financial Statements and MD&A

Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

What matters in this story

Sentiment in this article

Next reads from the same story arc

Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– HBSS

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

What matters in this story

Sentiment in this article

Next reads from the same story arc

Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– HBSS

Relationships in this article

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

GOSSAMER BIO DEADLINE MONDAY JUNE 1st: Bragar Eagel & Squire, P.C. Urges Gossamer Bio, Inc. (NASDAQ:GOSS) Investors with Large Losses to Contact the Firm Before Monday June 1st

ALDEYRA DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 29 Deadline in Securities Class Action First Filed by the Firm - ALDX

AISIX Solutions Inc. Provides Status Report of Annual Financial Statements and MD&A

Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice